Navigation Links
Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Date:1/9/2012

virus (LLOQ < 25 IU/ml) at 28 days. Currently 87% of patients in the 100 mg arm and 94% in the 50 mg arm had undetectable virus at a median of 8 weeks of treatment. There have been no virologic breakthroughs observed in the study to date.

"These interim results are encouraging as they confirm the antiviral activity and safety of IDX184 in combination with pegylated interferon and ribavirin," Eric Lawitz, M.D., of Alamo Medical Research, Camden Medical Center, stated. "Nucleotide drugs such as IDX184 are becoming an important component in the rapidly evolving treatment regimens for HCV. Eventually, the goal for treatment will be to reduce or eliminate reliance on interferon and to shift to all oral combinations of direct-acting antiviral agents that can reduce potential side effects and decrease the amount of time on therapy."

Ron Renaud, President and Chief Executive Officer of Idenix, commented, "We are very pleased with the interim results for IDX184 and with the progress we made in 2011 across our programs. In 2012, we will build on this progress and believe we are well positioned to play a major role in treating HCV patients for the foreseeable future."

ABOUT IDX184
IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2'-methyl guanosine, which includes Idenix's proprietary liver-targeting technology.  This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing. IDX184 is currently being developed under a partial clinical hold.

ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases.  Idenix's current focus is on the treatment of patients with hepat
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Idenix Reports Advancement of HCV Development Pipeline
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
7. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
10. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 “2014 Deep ... Industry” is a professional and in-depth research ... The report introduces Lubricant basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... 2014 The National Model Aviation Museum, ... is pleased to announce that it has been granted ... the United States Air Force. , The certification is ... concluded this spring with an on-site inspection by Sarah ... , The National Museum of the United States ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... U.S. subsidiary in Philadelphia Area -, PHILADELPHIA, ... in,vivo cellular imaging, announced today the appointment of ... U.S. subsidiary of Paris-based Mauna,Kea Technologies and develops ... which improves patient care by eliminating the,need for ...
... used to provide cost-efficient, easy to use ... collecting lung sputum samples for testing, ALBUQUERQUE, N.M., ... maker of patented early lung cancer detection,testing and other ... Acoustics, LLC, to collect lung sputum,samples in an upcoming ...
... be presented at AACR ... on Cancer Stem Cells -, TORONTO, Feb. 13 /PRNewswire-FirstCall/ ... developing the next wave of,antibody therapeutics, today announced that new ... antibody will be,presented at the AACR Special Conference on Cancer ...
Cached Biology Technology:Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc. 2Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans 2Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans 3ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 2ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 3ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 4
(Date:7/25/2014)... A study published online in the International ... novel approach to preventing cervical cancer based on findings ... after removal of a discrete population of cells in ... study that looked at squamocolumnar junction cells, or SCJ ... have been implicated as the origins of cervical cancer. ...
(Date:7/25/2014)... Prediabetes and Diabetes increasingly consume the healthcare ... immediate attention. , To address the ... impacting low-and middle-income countries, global leaders in ... research in diabetes prevention and development of ... important text. , This book on ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... Ariz. Humans are having an effect on Earth,s ecosystems ... warming of the planet we are causing. Now you can ... leaving behind. The only question is how large of an ... the current issue of Science (Dec. 16, 2011), ...
... Austen BioInnovation Institute in Akron (ABIA) and the U.S. ... ground-breaking collaboration to support and develop regulatory science for ... devices. Effective today, the FDA and ABIA executed ... to draw upon ABIA resourcesincluding a library of test ...
... 2011. Monitored by scientists at Kessler Foundation, six people with ... Ekso Bionics that enables wheelchair users to stand and walk. ... in October 2011. Five patients have paraplegia and one ... and had durations of injury from 4 months to 2 ...
Cached Biology News:Researchers assess effects of a world awash in nitrogen 2FDA, ABIA to collaborate on safety and performance of materials used in medical devices 2